Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment

A. McCleery, J. Ventura, R. S. Kern, K. L. Subotnik, D. Gretchen-Doorly, M. F. Green, G. S. Hellemann, K. H. Nuechterlein

Research output: Contribution to journalArticlepeer-review

99 Scopus citations

Abstract

Background: Although many studies have assessed cognitive functioning in first-episode schizophrenia (FESz), the pattern and severity of impairment across cognitive domains remain unclear. Moreover, few studies have directly compared the pattern of cognitive performance between FESz and chronic schizophrenia (CSz). In this study we examined the cognitive impairment profile in FESz using a standardized neurocognitive battery (MATRICS Consensus Cognitive Battery; MCCB). Methods: MCCB data were compared from 105 FESz patients, 176 CSz patients and 300 non-psychiatric (NP) participants. Mixed model analysis evaluated group differences in MCCB profiles and relative strengths and weaknesses in the MCCB profiles of patients. Clinical implications of MCCB performance were also examined; we compared the proportion of participants from each group who exhibited clinically-significant global cognitive impairment based on the MCCB Overall Composite score. Results: FESz and CSz showed impaired performance across all MCCB domains relative to NP. With the exception of relative preservation of working memory and social cognition in FESz, the MCCB domain scores were similar in FESz and CSz. The distribution of impairment on the Overall Composite score did not significantly differ between FESz and CSz; compared to NP, both patient groups were overrepresented in moderate and severe impairment categories. Conclusion: The pattern, magnitude, and distribution of severity of impairment in FESz were similar to that observed in CSz. However, early in the illness, there may be relative sparing of working memory and social cognition.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalSchizophrenia Research
Volume157
Issue number1-3
DOIs
StatePublished - Aug 2014
Externally publishedYes

Bibliographical note

Funding Information:
M.F. Green and K.H. Nuechterlein are officers within MATRICS Assessment, Inc., the publisher of the MCCB, but do not receive any financial remuneration for their respective roles. R.S. Kern is an officer for MATRICS Assessment, Inc. and receives financial compensation for his role within the non-profit organization. K.H. Nuechterlein has received unrelated research grants from Janssen Scientific Affairs (R092670SCH4005; RIS-NAP-4009), Genentech (ML28264), and Posit Science (BPI-1000-11) and has been a consultant to Otsuka and Genentech. J. Ventura has received funding from Genentech, Inc. ( C4-150335 ). He has served as a consultant to Brain Plasticity, Inc., and Boehringer-Ingelheim GmbH. K.L. Subotnik and D. Gretchen-Doorly have received research funding from Janssen Scientific Affairs, LLC, and Genentech, Inc., through grants to K.H. Nuechterlein and J. Ventura. K.L. Subotnik is a consultant to Otsuka America Pharmaceutical, Inc. M.F. Green has been a consultant to AbbVie, Biogen, DSP, FORUM Pharmaceuticals, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen Foundation ( 20130132 ). All other authors declare they have no conflicts of interest.

Funding Information:
A. McCleery is supported by the Canadian Institutes of Health Research fellowship award ( MFE-120919 ). FESz subject recruitment and data collection were supported by NIMH research grant MH037705 (K.H. Nuechterlein, PI) and Center grant MH066086 (K.H. Nuechterlein, PI). CSz and NP subject recruitment and data collection were supported by Contract N01MH22006 from the NIMH to the University of California, Los Angeles (S. Marder, PI; M.F. Green, Co-PI; W. Fenton, Project Officer).

Funding

M.F. Green and K.H. Nuechterlein are officers within MATRICS Assessment, Inc., the publisher of the MCCB, but do not receive any financial remuneration for their respective roles. R.S. Kern is an officer for MATRICS Assessment, Inc. and receives financial compensation for his role within the non-profit organization. K.H. Nuechterlein has received unrelated research grants from Janssen Scientific Affairs (R092670SCH4005; RIS-NAP-4009), Genentech (ML28264), and Posit Science (BPI-1000-11) and has been a consultant to Otsuka and Genentech. J. Ventura has received funding from Genentech, Inc. ( C4-150335 ). He has served as a consultant to Brain Plasticity, Inc., and Boehringer-Ingelheim GmbH. K.L. Subotnik and D. Gretchen-Doorly have received research funding from Janssen Scientific Affairs, LLC, and Genentech, Inc., through grants to K.H. Nuechterlein and J. Ventura. K.L. Subotnik is a consultant to Otsuka America Pharmaceutical, Inc. M.F. Green has been a consultant to AbbVie, Biogen, DSP, FORUM Pharmaceuticals, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen Foundation ( 20130132 ). All other authors declare they have no conflicts of interest. A. McCleery is supported by the Canadian Institutes of Health Research fellowship award ( MFE-120919 ). FESz subject recruitment and data collection were supported by NIMH research grant MH037705 (K.H. Nuechterlein, PI) and Center grant MH066086 (K.H. Nuechterlein, PI). CSz and NP subject recruitment and data collection were supported by Contract N01MH22006 from the NIMH to the University of California, Los Angeles (S. Marder, PI; M.F. Green, Co-PI; W. Fenton, Project Officer).

FundersFunder number
Posit ScienceBPI-1000-11
National Institutes of Health
National Institute of Mental HealthP50MH066286, R01MH037705, MH066086, N01MH22006
GenentechML28264, C4-150335
University of California, Los Angeles
Janssen Scientific AffairsR092670SCH4005, RIS-NAP-4009
Canadian Institutes of Health ResearchMFE-120919

    Keywords

    • Cognition
    • First episode schizophrenia
    • First-episode schizophrenia
    • MCCB
    • Profile analysis

    Fingerprint

    Dive into the research topics of 'Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) Profile of Impairment'. Together they form a unique fingerprint.

    Cite this